⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22857300 | 0.94 | — | — | |
| SCHEMBL24119915 | 0.93 | — | — | |
| SCHEMBL21288014 | 0.91 | — | — | |
| SCHEMBL16248521 | 0.89 | — | — | |
| SCHEMBL22692685 | 0.88 | — | — | |
| SCHEMBL22692645 | 0.87 | — | — | |
| SCHEMBL23026394 | 0.86 | KISS1R (0.35) | — | |
| SCHEMBL19929963 | 0.84 | — | — | |
| SCHEMBL16248579 | 0.81 | KDM4C (0.35) | — | |
| SCHEMBL19934894 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11840691-B2 | Compound and application thereof | KYLONOVA (XIAMEN) BIOPHARMA CO., LTD. (CN) | 2023-12-12 | — | — | US | disclosed |
| US-20230374513-A1 | NOVEL COMPOUND AND APPLICATION THEREOF | KYLONOVA (XIAMEN) BIOPHARMA CO., LTD. (CN) | 2023-11-23 | — | — | US | disclosed |
| US-20230357776-A1 | COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230357776-A1 | COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2023-11-09 | — | — | US | disclosed |
| US-11732265-B2 | Compositions and methods for modulating complement factor B expression | IONIS PHARMACEUTICALS, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11732265-B2 | Compositions and methods for modulating complement factor B expression | IONIS PHARMACEUTICALS, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11690818-B2 | Drug containing liver targeting specific ligand and thyroid hormone receptor agonist | KYLONOVA (XIAMEN) BIOPHARMA CO., LTD. (CN) | 2023-07-04 | — | — | US | disclosed |
| US-20230151365-A1 | COMPOSITIONS AND METHODS FOR MODULATING TTR EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230057718-A1 | COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2023-02-23 | — | — | US | disclosed |
| US-20220324900-A1 | COMPOSITIONS AND METHODS FOR MODULATING ANGIOPOIETIN-LIKE 3 EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2022-10-13 | — | — | US | disclosed |
| US-9181550-B2 | Compositions and methods for modulating apolipoprotein (a) expression | ISIS PHARMACEUTICALS, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-20150315594-A1 | COMPOSITIONS AND METHODS FOR MODULATING ANGIOPOIETIN-LIKE 3 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2015-11-05 | — | — | US | disclosed |
| US-9163239-B2 | Compositions and methods for modulating apolipoprotein C-III expression | ISIS PHARMACEUTICALS, INC. (US) | 2015-10-20 | — | — | US | disclosed |
| US-9145558-B2 | Compositions and methods for modulating HBV expression | ISIS PHARMACEUTICALS, INC. (US) | 2015-09-29 | — | — | US | disclosed |
| US-9127276-B2 | Conjugated antisense compounds and their use | ISIS PHARMACEUTICALS, INC. (US) | 2015-09-08 | — | — | US | disclosed |
| US-20150176007-A1 | COMPOSITIONS AND METHODS FOR MODULATING HBV EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2015-06-25 | — | — | US | disclosed |
| US-20150126718-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | ISIS PHARMACEUTICALS, INC. (US) | 2015-05-07 | — | — | US | disclosed |
| US-20150126719-A1 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2015-05-07 | — | — | US | disclosed |
| US-20150126720-A1 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN (a) EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2015-05-07 | — | — | US | disclosed |
| US-20140343123-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | ISIS PHARMACEUTICALS, INC. (US) | 2014-11-20 | — | — | US | disclosed |